Search research articles
Contact Us
Filters
Showing results (191-200 of 264) with videos related to
Page
of 27
Sort By:
JCI Insight
|
August 23, 2022
Multiparametric MRI to quantify disease and treatment response in mice with myeloproliferative neoplasms
Tanner H Robison, Manisha Solipuram, Kevin Heist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 28, 2010
NF1 inactivation in adult acute myelogenous leukemia
Brian Parkin, Peter Ouillette, Yin Wang, et al.
Bone Marrow Transplantation
|
December 22, 2022
Pneumocystis jirovecii Infection in autologous hematopoietic stem cell transplant recipients
John Coda, Kadee Raser, Sarah M Anand, et al.
Blood
|
October 11, 2003
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
Deborah A Thomas, Stefan Faderl, Jorge Cortes, et al.
JAMA Oncology
|
March 10, 2018
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial
John Mascarenhas, Ronald Hoffman, Moshe Talpaz, et al.
Hemasphere
|
May 10, 2021
Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial
Claire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Cancer
|
May 17, 2002
Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course
Srdan Verstovsek, Hui Lin, Hagop Kantarjian, et al.
Blood
|
October 13, 2007
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment
Andreas Hochhaus, Brian Druker, Charles Sawyers, et al.
Blood
|
February 1, 2007
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase
Francois Guilhot, Jane Apperley, Dong-Wook Kim, et al.
The New England Journal of Medicine
|
November 30, 2012
Ponatinib in refractory Philadelphia chromosome-positive leukemias
Jorge E Cortes, Hagop Kantarjian, Neil P Shah, et al.
Page
of 27
Search research articles
Search
Showing results (191-200 of 264) with videos related to
Sort By:
Page
of 27
JCI Insight
|
August 23, 2022
Multiparametric MRI to quantify disease and treatment response in mice with myeloproliferative neoplasms
Tanner H Robison, Manisha Solipuram, Kevin Heist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 28, 2010
NF1 inactivation in adult acute myelogenous leukemia
Brian Parkin, Peter Ouillette, Yin Wang, et al.
Bone Marrow Transplantation
|
December 22, 2022
Pneumocystis jirovecii Infection in autologous hematopoietic stem cell transplant recipients
John Coda, Kadee Raser, Sarah M Anand, et al.
Blood
|
October 11, 2003
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
Deborah A Thomas, Stefan Faderl, Jorge Cortes, et al.
JAMA Oncology
|
March 10, 2018
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial
John Mascarenhas, Ronald Hoffman, Moshe Talpaz, et al.
Hemasphere
|
May 10, 2021
Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial
Claire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Cancer
|
May 17, 2002
Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course
Srdan Verstovsek, Hui Lin, Hagop Kantarjian, et al.
Blood
|
October 13, 2007
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment
Andreas Hochhaus, Brian Druker, Charles Sawyers, et al.
Blood
|
February 1, 2007
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase
Francois Guilhot, Jane Apperley, Dong-Wook Kim, et al.
The New England Journal of Medicine
|
November 30, 2012
Ponatinib in refractory Philadelphia chromosome-positive leukemias
Jorge E Cortes, Hagop Kantarjian, Neil P Shah, et al.
Page
of 27